PCM
AVDL

Penserra Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Penserra Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-126,131
Closed -$1.93M – 1061
2025
Q3 		$1.93M Buy
+126,131
New +$1.64M 0.02% 341
2021
Q4 		– Sell
-1,335
Closed -$13K – 1380
2021
Q3 		$13K Buy
1,335
+5
+0.4% +$39 ﹤0.01% 1308
2021
Q2 		$8K Buy
1,330
+5
+0.4% +$40 ﹤0.01% 1286
2021
Q1 		$11K Sell
1,325
-135
-9% -$1.09K ﹤0.01% 1021
2020
Q4 		$9K Buy
+1,460
New +$9.13K ﹤0.01% 931

Other funds holding AVDL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Penserra Capital Management's AVDL Position: Q4 2025 in Review

Penserra Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q4 2025, closing a stake of 126,131 shares — an estimated $1.93M sold.

Penserra Capital Management first reported a position in AVDL in Q4 2020 and held it in 5 quarters. The position peaked at $1.93M in Q3 2025. 207 funds tracked by Wall St. Rank hold AVDL as of Q4 2025.

  • Penserra Capital Management reported no remaining Avadel Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Penserra Capital Management sold 126,131 Avadel Pharmaceuticals shares in Q4 2025, an estimated $1.93M.
  • Penserra Capital Management first reported a position in Avadel Pharmaceuticals in Q4 2020 and held it in 5 quarters.
  • Penserra Capital Management's Avadel Pharmaceuticals position peaked at $1.93M in Q3 2025.
  • 207 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2025.

Based on Penserra Capital Management's 13F filing for Q4 2025, filed 12 Feb 2026.